DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
Dexcom EVP Chief People & Culture Officer Sadie Stern reported a routine tax-withholding event related to equity compensation. On the reported date, 1,451 shares of Dexcom common stock were withheld at $71.90 per share to cover tax obligations from the net settlement of restricted stock units.
The footnotes clarify this was not an open-market sale, but shares retained by the company to satisfy required tax withholding and remittance. After this withholding, Stern directly held 130,059 Dexcom shares, including 74,753 unvested restricted stock units that vest on various schedules through March 8, 2029.
Dexcom EVP Jon Coleman had shares withheld to cover taxes on stock awards. On this Form 4, 7,362 shares of Dexcom common stock were surrendered at $71.90 per share to satisfy tax withholding obligations from the net settlement of restricted stock units, and this is explicitly stated not to be a sale.
After this tax withholding, Coleman directly holds 105,273 shares of Dexcom, including 95,450 unvested restricted stock units that are scheduled to vest in tranches through March 8, 2029 and May 22, 2029. This filing reflects routine compensation-related tax treatment rather than an open‑market trade.
Dexcom Executive Chair Kevin R. Sayer reported an open-market sale of 26,759 shares of Dexcom common stock on May 21, 2026 at $72.00 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on February 18, 2026, which is designed to allow the orderly disposition of his shares over time.
Following this sale, Sayer directly owns 382,482 Dexcom shares, which include 106,972 unvested restricted stock units. These unvested units stem from grants made on March 8, 2024, 2025, and 2026, each scheduled to vest gradually through dates between 2027 and 2028.
Dexcom Inc. executive vice president and chief legal officer Michael Jon Brown sold 1,700 shares of common stock on May 15, 2026 in an open-market trade at $59.91 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on November 26, 2025. After the transaction, he holds 109,504 shares directly, including 77,603 unvested RSUs that are scheduled to vest in tranches through March 8, 2029.
Michael Brown reported securities sales and a planned restricted-stock sale. The filing lists sales of 1,700 shares of Common Stock on 04/15/2026 for $107,168.00 and 1,700 shares on 03/16/2026 for $110,245.00. The form also shows 1,700 restricted shares referenced with a 03/08/2026 trade date and Morgan Stanley Smith Barney LLC as the broker.
Dexcom, Inc. used its 2026 Investor Day to outline long-term growth and profitability goals and announce a major capital return plan. The company is targeting organic revenue growth of at least 10% every year through 2030, with 2030 non-GAAP gross margin of 67–69%, non-GAAP operating margin of 29–30%, and adjusted EBITDA margin of 36–37%.
Dexcom’s board also authorized a new share repurchase program of up to $1.0 billion of common stock, with repurchases permitted through June 30, 2027. At the same time, the board terminated the prior repurchase program, which had $250.0 million remaining. Repurchases are discretionary and may be made in the open market, privately negotiated transactions, or under Rule 10b5-1 trading plans, in accordance with Rule 10b-18 and other laws.
Dexcom Inc. director Bridgette P. Heller reported an open-market sale of 1,012 shares of common stock at $60.01 per share. After the transaction, she directly holds 25,007 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on August 14, 2025, which provides for orderly share dispositions.
DexCom affiliate reported proposed sales of Common Stock on a Form 144. The filing lists a brokerage entry showing 60,730.12 shares with a broker reference to Fidelity Brokerage Services and date 05/12/2026, and a separate entry showing 68,826.12 shares tied to 02/12/2026. The filing references restricted stock vesting and compensation as the source for securities.
DEXCOM INC director Nicholas Augustinos reported non-cash share transfers on Form 4. He recorded two bona fide gift transactions involving a total of 10,092 shares of common stock, tied to the vesting of previously awarded restricted stock units and movement of shares into the Kirschner/Augustinos Revocable Trust.
Following these transactions, Augustinos holds 38,457 shares indirectly through the revocable trust, with no shares reported as held directly. No open-market purchases or sales were reported, and the transactions involved a price of $0.00 per share.